FindTrial
Sign In

To analyze the role of perioperative administration of dexmedetomidine on the incidence and severity of chronic pain, in cases operated for breast cancer

Effect of Perioperative infused Dexmedetomidine on chronic pain after breast surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/11/002178
Enrollment
86
Registered
2011-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Breast cancer

Interventions

Intervention1: Group D: Dexmedetomidine infusion IV: dexmedetomidine (2 µg/ml) in group D in a loading dose of 0.5 ml/kg IV 30 min prior to induction, followed by a continuous infusion of 0.25 ml/kg/

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 86 ASA physical status I or II female patients, aged >18 yrs, BMI 25+/-20%, posted for breast cancer surgery

Exclusion criteria

Exclusion criteria: current history of psychiatric disorder, presently on psychotropic, α 2-agonists or opiod medications within 28 days before surgery, any end organ dysfunction, pregnancy, alcohol abuse, smoking habit.

Design outcomes

Primary

MeasureTime frame
Brief Pain Inventory, Short Form McGill Pain Questionnaire, quality of life ScoreTimepoint: 3 months after surgery—

Secondary

MeasureTime frame
Verbal numerical scoreTimepoint: 10, 30, 60, and 120 min and at 6, 12, 24, 36, 48, and 72 hr postoperatively;fentanyl requirementTimepoint: Intraoperatively;Isoflurane concentrationTimepoint: Intraoperatively;Radiotherapy/chemotherapy/anti-estrogen therapyTimepoint: 3 months after surgery;Ramsay sedation scoreTimepoint: 10, 30, 60, and 120 min and at 6, 12, 24, 36, 48, and 72 hr postoperatively—

Countries

India

Contacts

Public ContactGaurav Jain

Teerthankar Mahaveer Medical college

gauravhld@gmail.com9936871711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026